NCT06023030
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 32 versions: 28 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 6 words Show 4 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Nov 2026 to Sep 11, 2026
- Enrollment target: estimated 240 to confirmed 253
- Site details revised at 104 of 104 sites
- Minor Study sites: 101 to 104
- Study completion date: Nov 2026 to May 2027
- Minor Study sites: 94 to 101v30
- Minor Study sites: 87 to 94v29
- Minor Study sites: 83 to 87v28
Show 22 earlier versionsHide 22 earlier versions
- Minor Study sites: 82 to 83v27
- Minor Study sites: 81 to 82v26
- Minor Study sites: 73 to 81v25
- Minor Study sites: 71 to 73v24
- Minor Study sites: 70 to 71v23
- Minor Study sites: 66 to 70
- Primary and study completion dates: Nov 30, 2026 to Nov 2026
- Minor Study sites: 65 to 66v20
- Minor Study sites: 64 to 65v19
- Minor Study sites: 61 to 64v18
- Minor Study sites: 59 to 61v17
- Minor Study sites revised (59)v16
- Minor Study sites: 39 to 59v15
- Minor Study sites: 36 to 39v13
- Minor Study sites: 35 to 36v12
- Minor Study sites: 34 to 35v11
- Minor Study sites: 27 to 34v10
- Minor Study sites: 26 to 27v8
- Minor Study sites: 25 to 26v7
- Minor Study sites: 14 to 25v5
- Minor Study sites: 12 to 14v4
- Minor Study sites: 3 to 12v3
- Minor Study sites: 2 to 3v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of Participants with Drug Related Serious Infections
Timeframe: Up to 64 Weeks
Arms and interventions
Upadacitinib
Participants will receive upadacitinib as prescribed by their physician according to local label.
Sites
104 sites in 1 country